Suppr超能文献

利培酮治疗自闭症儿童和青少年的效果:系统评价和荟萃分析。

Effects of Risperidone in Autistic Children and Young Adults: A Systematic Review and Meta-Analysis.

机构信息

Universidade Federal de Sao Joao del-Rei, Campus Centro-Oeste Dona Lindu, Divinopolis, Minas Gerais, Brazil.

Department of Psychobiology (Departamento de Psicobiologia), Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil.

出版信息

Curr Neuropharmacol. 2021;19(4):538-552. doi: 10.2174/1570159X18666200529151741.

Abstract

There are several studies investigating the effects of risperidone on autism, but many of these studies are contradictory or inconclusive. This systematic review and meta-analysis investigated the effects of risperidone on five domains of the Aberrant Behaviour Checklist (ABC) scale on Autism Spectrum Disorder (ASD), as well as weight gain and waist circumference. The protocol for the present systematic review and meta-analysis was registered on the International Prospective Register of Systematic Reviews (PROSPERO). For this study, we analysed articles (2,459), selecting them according to the PICOS strategy (Population, Intervention, Comparison, Outcome, Study design). Although risperidone is effective for the treatment of lethargy and inadequate speech, concerns about the association between weight gain, waist circumference and risperidone require a need for evaluation of the risk-benefit ratio in its use. There was a significant association between weight gain, waist circumference and risperidone. In conclusion, it was possible to suggest the efficacy of risperidone for the treatment of lethargy and inadequate speech. Finally, we emphasize that the risk-benefit in its use should be evaluated (Protocol number CRD42019122316).

摘要

有几项研究调查了 risperidone 对自闭症的影响,但其中许多研究结果相互矛盾或不确定。本系统评价和荟萃分析调查了 risperidone 对自闭症谱系障碍(ASD)异常行为检查表(ABC)五个领域的影响,以及体重增加和腰围。本系统评价和荟萃分析的方案已在国际前瞻性系统评价注册库(PROSPERO)中注册。在这项研究中,我们分析了文章(2459 篇),根据 PICOS 策略(人群、干预、比较、结局、研究设计)选择了它们。虽然 risperidone 对治疗嗜睡和言语不足有效,但体重增加、腰围和 risperidone 之间的关联令人担忧,需要评估其使用的风险效益比。体重增加、腰围和 risperidone 之间存在显著关联。总之, risperidone 治疗嗜睡和言语不足的疗效是可以被证明的。最后,我们强调应该评估其使用的风险效益(方案编号 CRD42019122316)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a97/8206457/7903e0e39897/CN-19-538_F1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验